Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma-Reference-Cited by-同舟云学术

Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma

Published:2015-06-26 Issue:6 Volume:10 Page:e0128662
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Watanabe Takashi,Mitsuhashi Masato,Sagawa Morihiko,Ri Masaki,Suzuki Kenshi,Abe Masahiro,Ohmachi Ken,Nakagawa Yasunori,Nakamura Shingen,Chosa Mizuki,Iida Shinsuke,Kizaki Masahiro

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference47 articles.

1. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma;JF San Miguel;N Engl J Med,2008

2. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma;PG Richardson;N Engl J Med,2005

3. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial;PG Richardson;Blood,2007

4. Hypodiploidy is a major prognostic factor in multiple myeloma;NV Smadja;Blood,2001

5. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy;T Facon;Blood,2001

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib;Cancers;2021-02-25

2. Tumor inhibition or tumor promotion? The duplicity of CXCR3 in cancer;Journal of Leukocyte Biology;2020-08